<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bartko, D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">RIS with Dissemination on MRI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-9</style></pages><abstract><style  face="normal" font="default" size="100%">Although disease-modifying therapies work best when given early in MS, the decision to proactively treat patients with radiologically isolated syndrome (RIS) is countered by the increasing risks associated with disease-modifying therapies as well as the uncertain prognostic outcome of RIS [Spain R, Bourdette D. Curr Neurol Neurosci Rep 2011].</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>